VRNA vs. LMN.V

Last updated Jun 9, 2026

VRNA (Verona Pharma plc) and LMN.V (Lumine Group Inc) are both stocks. VRNA operates in Biotechnology (Healthcare), while LMN.V operates in Software - Application (Technology). At a 0.02 correlation, their price movements are largely independent.

Performance

VRNA vs. LMN.V - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Verona Pharma plc (VRNA) and Lumine Group Inc (LMN.V). The values are adjusted to include any dividend payments, if applicable.

Different Trading Currencies

VRNA is traded in USD, while LMN.V is traded in CAD. To make them comparable, the LMN.V values have been converted to USD using the latest available exchange rates.

Returns By Period

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

LMN.V

• 1D: -3.47%
• 1M: 9.68%
• YTD: -18.04%
• 6M: -21.12%
• 1Y: -51.91%
• 3Y*: 4.01%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

VRNA vs. LMN.V - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	0.15%
LMN.V Lumine Group Inc	-18.04%	-30.87%	26.85%	90.78%

Correlation

The correlation between VRNA and LMN.V is -0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.04
Correlation (3Y) Calculated over the trailing 3-year period	0.01
Correlation (All Time) Calculated using the full available price history since Mar 24, 2023	0.02

Fundamentals

Market Cap VRNA : $9.72B LMN.V : CA$5.81B
EPS VRNA : -$0.69 LMN.V : CA$0.48
PS Ratio VRNA : 57.97 LMN.V : 7.03
PB Ratio VRNA : 34.92 LMN.V : 7.00
Total Revenue (TTM) VRNA : $167.65M LMN.V : CA$792.89M
Gross Profit (TTM) VRNA : $159.52M LMN.V : CA$271.95M
EBITDA (TTM) VRNA : -$40.86M LMN.V : CA$253.96M

Return for Risk

VRNA vs. LMN.V — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LMN.V

LMN.V Risk / Return Rank: 10
LMN.V Sharpe Ratio Rank: 6
LMN.V Sortino Ratio Rank: 5
LMN.V Omega Ratio Rank: 7
LMN.V Calmar Ratio Rank: 13
LMN.V Martin Ratio Rank: 18

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VRNA vs. LMN.V - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and Lumine Group Inc (LMN.V). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	VRNA	LMN.V	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	-0.98	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.23	—

Drawdowns

Drawdown Indicators

	VRNA	LMN.V	Difference
Max Drawdown Largest peak-to-trough decline	—	-66.63%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-66.63%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-66.63%	—
Current Drawdown Current decline from peak	—	-59.17%	—
Average Drawdown Average peak-to-trough decline	—	-17.94%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	45.57%	—

Volatility

Volatility by Period

	VRNA	LMN.V	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	14.52%	—
Volatility (6M) Calculated over the trailing 6-month period	—	38.97%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	53.25%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	45.36%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	45.36%	—

Dividends

VRNA vs. LMN.V - Dividend Comparison

Neither VRNA nor LMN.V has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

VRNA vs. LMN.V - Profitability Comparison

The chart below illustrates the profitability comparison between Verona Pharma plc and Lumine Group Inc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

LMN.V - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Lumine Group Inc reported a gross profit of 43.76M and revenue of 204.93M. Therefore, the gross margin over that period was 21.4%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

LMN.V - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Lumine Group Inc reported an operating income of 28.74M and revenue of 204.93M, resulting in an operating margin of 14.0%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

LMN.V - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Lumine Group Inc reported a net income of 18.70M and revenue of 204.93M, resulting in a net margin of 9.1%.

Frequently Asked Questions

Can I hold both VRNA and LMN.V in my portfolio?

VRNA and LMN.V have a correlation of -0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.